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Amino-terminal acetylation is a ubiquitous protein modification affecting the
majority of eukaryote proteins to regulate stability and function. We describe
an optimised recombinant expression system for rapid production of amino
terminal-acetylated proteins within bacteria. We go on to describe the sys-
tem’s use in a fluorescence based in vivo assay for use in the high-throughput
screen to identify drugs that impact amino-terminal acetylation-dependent
oligomerisation. These new tools and protocols will allow researchers to
enhance routine recombinant protein production and identify new molecules
for use in research and clinical applications.
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Amino-terminal (Nt) acetylation is a ubiquitous co- and
post-translational modification affecting up to 90% of
the eukaryote proteome [1]. Eukaryote cells can possess
up to six different amino-a-acetyl-transferase complexes
(Nat A-F), each capable of conjugating an acetyl group
onto the amino-terminal residue of a protein, according
to its amino-terminal dipeptide [2]. This global protein
modification has diverse effects upon protein structure,
stability and function by inhibiting amino proteolysis,
modulating membrane interactions and protein folding
and providing a signal for protein–protein interactions.
These modifications impact a large number of cellular
processes including cytoskeletal organisation, signalling,
ER translocation, cell cycle progression, protein degra-
dation and apoptosis [2–5], as well as resistance to viral
infection and disease states such as a-synucleinopathies,
heart disease and cancer [4,6–9]. Thus, Nat complexes
are attractive targets for drug-based therapies.
a-synuclein (aSyn) is an essential mammalian pro-
tein making up ~ 1% of the cytosolic proteome within
neurons. It localises to presynaptic terminals and while
its precise cellular function is unknown it is thought to
somehow play a role in regulating vesicle turnover at
synaptic termini [10]. aSyn is largely unstructured
when cytosolic, but in the presence of membranes it
acquires an a-helical folded structure capable of dimer
and subsequent oligomer formation. This oligomerisa-
tion is in part modulated by an array of post-transla-
tional modifications which include amino-terminal
acetylation and multiple phosphorylation events [11].
Structural studies have indicated the stability of the
amino-terminal a-helical structure and subsequent
membrane interactions are regulated by Nt-acetylation
of the aSyn protein [8,12–15]. These modifications, the
oligomerisation status, and mutations within the
SNCA gene (encodes for aSyn) are all major factors in
Abbreviations
BiFC, Bimolecular Fluorescence Complementation; IPTG, isopropyl b-D-1 thiogalactopyranoside; Nt, Amino-terminal; Nat, amino-a-acetyl-
transferase; aSyn, a-synuclein.
1FEBS Letters (2017) ª 2017 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
aSyn fibril and aggregate formation, and each are key
influences in the pathology of a-synucleinopathies,
such as Parkinson’s disease.
Although Nt-acetylation does occur in bacteria, it
occurs to a significantly lesser extent when compared
to eukaryotes [16]. Prokaryotes lack the amino-a-
acetyltransferase complexes required for efficient N-
terminal acetylation which occurs to the majority
(~ 90%) of eukaryote proteins. In order to generate
significant Nt-acetylated proteins for subsequent bio-
chemical and structural assays researchers rely upon
either eukaryote expression systems or postpurification
in vitro amino-terminal acetylation reactions, each of
which has significant time and cost implications. By
applying a novel recombinant bacterial N-terminal
acetylation system developed within this lab [17] it is
possible to acetylate the amino-terminal residue of
recombinant proteins, which has allowed researchers
to establish this modification has a significant impact
upon the structural conformation and binding proper-
ties of diverse proteins from a plethora of cell types
[3,6–8,12–15]. This initial molecular tool for producing
modified recombinant proteins was limited to its abil-
ity to only Nt-acetylate substrates of the NatB com-
plex (i.e. proteins starting with M-D-, M-E-, M-N- or
M-Q-). In addition the efficiency of substrate Nt-acety-
lation when using this system was not 100% efficient
for all target proteins, and therefore did not always
permit the production and purification of a homoge-
nous Nt-acetylated substrate.
Here, we describe an expanded and improved recom-
binant Nt-acetylation system where coexpression with
either the fission yeast NatA or NatB complex allows
the production of Nt-acetylated proteins from
Escherichia coli that allows modification of more than
50% of the eukaryote proteome with 100% efficiency.
We go on to show this system has no detectable impact
upon the health or expression levels of target proteins
within the bacterial cell facilitating large-scale produc-
tion of Nt-modified proteins. Furthermore, we describe
how this screen can be applied in high-throughput fluo-
rescence-based assays to identify drugs that impact pro-
tein oligomerisation by applying it to identify molecules
which modulate aSyn amyloid formation.
Materials and methods
Extended optimised recombinant Nt-acetylation
system
Sequence optimised cDNA encoding for catalytic and regula-
tory subunits of the fission yeast NatA (naa10 and naa15) and
NatB (naa20 and naa25) complexes were generated
synthetically (Thermofisher, Waltham, MA USA) and cloned
into pACYCDUET expression vectors (Novagen, Merck,
Darmstadt, Germany) to generate pNatA and pNatB (avail-
able from http://www.addgene.org/Dan_Mulvihill/).
Generation of Prha and BiFC expression vectors
The Prha promoter [18] was cloned into pET3a (Novagen)
together with cDNA encoding for either the rabbit a-
skeletal muscle tropomosin (Tpm1.1) or mouse Tpm4.2
isoforms to create pRham-aSkTm and pRham-Tm4.2
respectively. cDNA encoding for the amino- and carboxyl-
half fluorophore fragments from an enhanced mVenus-
based BiFC system [19] were synthesised and cloned into
the discrete multicloning sites of pETDUET-1 (Novagen)
to generate pET-BiFC. aSyn cDNAs were amplified as
Nco1-BamH1 and Nde1-BglII fragments and ligated into
pET-BiFC to create pET-aSyn-BiFC.
Induction of Nat complex and target substrate in
E. coli
BL21(DE3) competent cells containing pNatA or pNatB (con-
tain chloramphenicol selection markers) were generated and
subsequently transformed with target protein expression plas-
mids. Induction cultures were inoculated from overnight star-
ter cultures and allowed to grow with rapid shaking until
reaching an OD595 of 0.4–0.5. For sequential induction, expres-
sion of the Nat complexes was induced by first culturing in
100 mgL1 IPTG for 2 h before adding L-rhamnose (to a
concentration of 0.2% w/v) to induce production of substrate
protein. Glucose was added to the culture 1 h before cell har-
vesting to repress Prha-dependent transcription and ensure all
the synthesised target protein had associated with the Nat
complex. During BiFC assays expression, Nat complex and
BiFC tag-labelled proteins were induced simultaneously by cul-
turing in 20 mgL1 IPTG. Proteins were purified and sub-
jected to electron-spray mass spectroscopy to determine
efficiency of amino-terminal acetylation.
Monitoring growth and fluorescence of cell
cultures – plate readers and microscopy
Cell growth and fluorescence of cultures were followed in
96-well fluorescence assay plates (Brand noncoated Pure-
grade S) using a BMG Spectrostar Nano plate reader, shak-
ing cells at 37 °C. mCerulean3 and Venus BiFC fluorescent
proteins were excited at 433 and 500 nm wavelengths
respectively. Experimental cultures were inoculated from
overnight starter cultures, which were grown to mid-log
phase and diluted in fresh media containing antibiotic and
20 mgL1 IPTG, to an OD595 of 0.01, and dispensed into
the plate wells using an automated multidispense pipette.
The outer most plate wells were not used and all readings
were corrected for plate position-dependent variation in
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fluorescence. Data points on all growth curves were calcu-
lated from averages of > 3 replicate cultures on the same
plate. Each experiment was repeated on at least three inde-
pendent occasions and representative curves are shown here.
Results
Nt-acetylation system
We have previously described a recombinant Nt-acety-
lation system for producing Nt-modified proteins
within the E. coli cell. Although this worked well for
some NatB substrates, such as the fission yeast tropo-
myosin, its use often resulted in only a subpopulation
of the purified target protein having the amino-terminal
methionine modified, sometimes as little as 25% [17].
To improve the efficiency of the recombinant Nt-acety-
lation system and extend the technology to enable mod-
ification of the majority of eukaryotic proteomes we
generated new constructs. These expressed sequence
optimised components of the fission yeast NatA and
the NatB complexes (Fig. 1A) and in combination
these complexes are responsible for the Nt-acetylation
of more than 50% of the eukaryotic proteome [2]. The
amino-termini of NatA substrates (e.g. M-A-, M-T-,
M-S-, etc.) are processed by a methionine aminopepti-
dase, present in E. coli [20], prior to Nt-acetylation of




Fig. 1. Bacterial Nt-acetylation expression system. (A) Schematic outline of Nat constructs containing genes encoding catalytic and
regulatory subunits of the each Nt-acetylation complex under the control of T7 promoters. Expression of the substrate from a separate
construct is under the control of the rhamnose promoter. (B) Cell lysates from BL21(DE3) cells containing either pRham-Tm4.2 (left),
pRham-Tm4.2 and pNatA (middle), or pRham-aSkTm and pNatB (right) were separated by SDS/PAGE following sequential addition of IPTG
and Rhamnose, and visualised using coomassie stain. * and ** denote bands corresponding to Nat regulatory and catalytic subunits
respectively. (C) Summary of amino-termini tested and Nt-acetylation efficiency. Culturing cells at lower temperatures as well as reducing
the strength of target protein induction (by adding reduced quantities of IPTG/rhamnose) also resulted in improved Nt-acetylation efficiency.
We have observed 100% Nt-acetylation of a number of target proteins (e.g. Tpm, Calmodulin) when cells are cultured in minimal media
(e.g. for 15N labelling of proteins), however, isotope-enriched rich media (NZY) can improve Nt-acetylation in some cases.
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extracts from E. coli cells containing the pNatA or
pNatB constructs revealed strong and clearly defined
bands that migrated at the expected sizes for each com-
ponents of the Nat complexes (Fig. 1B), the majority
of which was soluble (not shown).
As well as optimising the expression of the Nat pro-
teins to improve the efficiency of the system, we decided
to employ bacterial expression constructs in which tran-
scription of the gene encoding for a recombinant pro-
tein can be induced independently of the Nat
complexes. By putting the expression of the target pro-
tein under the control of the Prha rhamnose-inducible
promoter [21], not only are the Prha and T7 promoters
triggered independently of each other, allowing sequen-
tial induction of different proteins within the cell, but
postinduction transcription from the Prha promoter
can be subsequently suppressed by the addition of glu-
cose to the growth media. We made use of this to pre-
cisely control the sequential induction of the Nat
complex followed by the transient production of the
protein to be acetylated (Fig. 1B). This strategy ensures
the Nat complex is present in excess during expression
of its substrate and allows the researcher to repress
induction of the target protein for a period before har-
vesting to ensure that all of the target Nat substrate
proteins are Nt-acetylated prior to cell harvesting.
Validation of expanded Nt-acetylation system
The efficiency of the new bacterial Nt-acetylation sys-
tem was tested upon different substrates of the NatA
and NatB complex. Tropomyosins are conserved
cytoskeletal proteins and Nt acetylation is critical for
their proper structural organisation, localisation and
function [22]. Sequential induction of the appropriate
optimised Nat complex followed by expression and
repression of different Tropomyosins resulted in Nt-
acetylation of 100% of the purified isoforms tested.
Similar efficiencies were also observed with proteins
with representative amino-terminal sequences for each
Nat substrate, including calmodulin and the neuronal
protein, a-synuclein (Fig. 1C). The diversity of amino-
terminal sequences between these proteins illustrates
the efficiency and versatility of this new recombinant
modification system, and permits Nt-acetylation of the
majority of eukaryotic proteins within E. coli.
The Nt-acetylation systems do not impact cell
growth or production of folded recombinant
proteins
Recombinant expression of Nat complexes has the poten-
tial to lead to a synthetic modification to the bacterial
proteome, which could impact cell growth. However,
growth curves generated from E. coli containing either
pNatA, pNatB or the empty parental pACYCDUET vec-
tor were indistinguishable (Fig. 2A). Similarly, levels of
correctly folded substrates which had been fused to fluo-
rescent proteins (as measured by fluorescence – Fig. 2B)
or cell growth (not shown) were unaffected by coexpres-
sion with the different Nat complexes. Not only were the
expression of substrates tagged at their carboxyl terminus
with the monomeric fluorescent protein, Cerulean3, unaf-
fected (Cdc8-Cer3/aSyn-Cer3) but these data show that
the NatA-dependent Nt-acetylation of the fluorescent
protein when fused to the amino terminus of the fission
yeast Tpm (Cer3-Cdc8) does not affect protein expression,
folding or fluorescence.
A BiFC-based method for monitoring Nt-
acetylation-dependent interactions and
oligomerisation
Bimolecular Fluorescence Complementation (BiFC) is a
powerful tool for exploring protein–protein interactions
within a cell. In this assay, cells express the two halves of
a fluorescent protein fused to two potential interacting
proteins. If these come into close proximity with each
other in an appropriate conformation the fluorophore
halves can also be brought together to form a stable func-
tional fluorophore. Using this assay in combination with
the recombinant Nt-acetylation system provides an ele-
gant and simple in vivo system to screen for modulators
of Nt-acetylation-dependent complex formation within
E. coli. To confirm the validity of any Nt-acetylation-
dependent variation in BiFC signal a BiFC construct was
generated encoding for each half of an enhanced Venus-
based BiFC reporter [19]. No differences were observed
in Venus fluorescence between cultures of E. coli cells
expressing the BiFC fluorophore fragments and either
Nat complex. This illustrates that NatA or NatB amino-
terminal acetylation does not affect the fluorescence or
stability of the BiFC complex (Fig. 2C).
The amino-terminal a-helical domain of aSyn and sub-
sequent oligomer formation is stabilised by Nt-acetylation
[13]. Consistent with this aSyn oligomers are observed in
boiled and SDS-treated extracts from NatB complex con-
taining bacterial cells, a significant proportion of which
was observed in the pellet fraction after high speed cen-
trifugation (not shown). Thus, NatB-dependent Nt-acety-
lation promotes stable aSyn oligomer formation within
E. coli. A BiFC-based assay therefore was developed to
monitor this NatB-dependent a-synuclein oligermisation
within E. coli cells.
A BiFC construct was generated encoding for a pair
of aSyn carboxyl terminal fusions conjugated to each
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half of the same enhanced Venus-based BiFC reporter
[19]. Venus fluorescence from cultures of NatB cells
containing the aSyn-BiFC reporter plateaued within
4 h. Fluorescence from equivalent NatA cells increased
to twice the signal within the same time frame
(Fig. 3A). This dramatic difference in BiFC signal was
not reflected in any measurable difference in fusion
protein production (Fig. S1) or cell growth rate
(Fig. 3A). This indicates NatB-dependent acetylation
of aSyn promotes an oligomeric conformation where
the carboxyl regions of the aSyn carboxyl termini are
in a distinct conformation to that of the nonacetylated
state.
This Nt-acetylation-dependent difference in signal was
also observed when the cells were visualised by live-cell
imaging. A strong aSyn-BiFC signal was observed
throughout the cytosol of cells lacking the NatB complex
(Fig. 3B). This signal was significantly lower in NatB cells
and was associated with the appearance of Congo Red
(Fig. 3B) or Niad 4 (not shown) stained amyloid struc-
tures [23]. This is consistent with recent structural studies
which show that Nt-acetylated aSyn forms stable antipar-
allel oligomers, which have been suggested initially inter-
act together as tetramers [24] and subsequently form
larger plaque-like structures [15]. However, the precise
impact Nt-acetylation has upon the aSyn structure and
oligomerisation remains a matter of significant debate. In
contrast, unmodified aSyn is more disordered and can
align parallel to each other, resulting in an increased BiFC
signal, and have a reduced propensity to incorporate into
larger complex structures [25,26] (Fig. S1).
A high-throughput screen for aSyn
oligomerisation affecters
Molecules that modulate aggregate formation provide




Fig. 2. Bacterial Nt-acetylation systems do not inhibit cell growth
or production of target substrate proteins. (A) Growth curves
generated from averages from 10 replicate cultures of BL21(DE3)
E. coli cells containing an empty pACYCDUET vector (dashed lines
and empty circles), pNatA (grey lines & grey filled circles) or pNatB
(black lines and black filled circles), all grown on the same 96-well
plate. Expression of NatA or NatB does not impact bacterial
growth. (B) Cerulean fluorescence signal from cultures of BL21
(DE3) cells contained pJC20-cerulean3-cdc8 (triangles), pJC20-
cdc8-cerulean3 (diamonds) pJC20-aSyn-cerulean3 (circles) together
with either pNatA (empty shape) or pNatB (filled shape).
Expression of NatA or NatB does not impact expression of
coexpressed recombinant proteins. (C) Yellow fluorescence signal
from BL21(DE3) cells containing pET-BiFC together with either
pNatA (empty square) or pNatB (filled squares) illustrate Nt-
acetylation does not impact BiFC fluorescence.
5FEBS Letters (2017) ª 2017 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
T. A. Eastwood et al. Recombinant Nt-acetylation and BiFC assay
a-synucleinopathies [27–29]. Having established this
aSyn-BiFC system provides a simple mechanism to
monitor aSyn oligomer and plaque formation within
the overnight cultures of bacterial cells, we decided to
test whether it could be used to screen for molecules
that impact this Nt-acetylation-dependent complex
organisation. A preliminary screen was undertaken
using a bank of FDA-approved drugs available within
the lab. While none of the drugs tested affected bacte-
rial cell growth a subset of tyrosine kinase inhibitors
specifically reduced the BiFC signal from Nt-acetylated
aSyn (Fig. 3C). In contrast, the same molecules did
not affect the BiFC signal, and therefore conforma-
tion, of nonacetylated aSyn (not shown), also indicat-
ing they did not disrupt BiFC-dependent fluorescence.
This group of cancer therapy drugs have previously
been shown to not only impact amyloid formation by
inhibiting aSyn kinases (such as C-Abl) and promote
degradation in vivo but also improve motor neuron
activity in a-synucleinopathy models [30–32].
These data provide evidence to validate this simple
and rapid high-throughput screening method to iden-
tify molecules that change the rate of Nt-acetylation-
dependent oligomer formation. This can be applied
with automated high-throughput technologies to iden-
tify novel therapies for Parkinson’s disease and other
Nat activity associated pathologies [9,33].
Discussion
Here, we describe a simple, quick, efficient and cheap
method for producing amino-terminally acetylated
proteins from E. coli. We have improved the capability
of an earlier system and provide the opportunity to
Nt-acetylate more than 50% of the proteome. In this
method, the protein only has to be expressed and puri-




Fig. 3. An in vivo BiFC system to identify Nt-acetylation state-
specific aSyn oligomerisation. (A) Growth (empty circles) and
fluorescence (filled circles) curves of BL21(DE3) cells containing
pET-aSyn-BiFC together with either pNatA (grey shapes) or pNatB
(black shapes) show while aSyn Nt-acetylation does not impact cell
growth (OD595), it affects BiFC signal from aSyn oligomers (Au).
(B) aSyn-BiFC fluorescence (upper panels, green bottom panels)
and Congo Red staining (middle panels, magenta bottom panels) of
BL21(DE3) cells containing pET-aSyn-BiFC with either pNatA (left
panels) or pNatB (right panels) indicate Nt-acetylation promotes
aSyn amyloid formation in bacteria. (C) Fluorescence (filled circles)
curves of BL21(DE3) cells containing pET-aSyn-BiFC and pNatB
grown in the presence of DMSO (empty circles), 5 mM Gefitinib
(filled diamonds), 5 mM Imatinib (filled circles) or 5 mM Lapatinib
(filled triangles) illustrate this class of tyrosine kinase inhibitors
promote formation of amyloids of Nt-acetylated aSyn.
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for additional, often complex and inefficient in vitro
acetylation steps. This system provides significant ben-
efits over in vitro Nt-modification systems in both time
(these reactions are not 100% efficient, take significant
time to optimise and require additional purification
steps, where protein yield is reduced) and costs (while
acetyl-coA, the source of the acetyl group, is abundant
within the E. coli, it is costly to purify or purchase).
We have shown that expression from the Nat com-
plexes does not impact the health or growth rate of
the bacterial culture, nor does it reduce the amount of
target protein that is expressed within the E. coli. In
addition, we and others have reported that Nt acetyla-
tion also stabilises protein in the bacterial cells and
results in an increased yield [17], thus providing an
opportunity to improve efficiency.
In this improved system we have also introduced a
sequential induction system which allows the target
recombinant protein to be induced when the Nat com-
plex is in abundance within the E. coli cytosol. This is
achieved through differential transcriptional control of
the Nat complex and target proteins. In this way the
target protein is induced after the Nat complex, and
repressed before cell harvesting, while the Nat complex
is still being produced.
Interestingly, as reported elsewhere, we have found
that the use of minimal media and reduced culture
temperatures (20 °C) can lead to improved quality and
Nt-acetylation efficiency of target proteins [12], as this
is likely to slow down peptide translation and also
facilitate improved protein folding.
We also describe a new Bi-Molecular Fluorescence
Complementation assay for monitoring Nt-acetylation-
dependent oligomerisation of proteins. In this assay it
was possible to monitor the oligomerisation state of
the human neuronal protein, a-synuclein, and forma-
tion of amyloid structures within the bacterial cell.
The molecular-genetic plasticity allowed by the bacte-
rial cell allows the opportunity to simply determine
which key factors (such as membrane lipid composi-
tion, temperature, stress, etc.) are critical in promoting
the fibril or amyloid forms of a-Syn. This BiFC Nat
assay method is now being applied within this lab to
study Nt-acetylation regulation-dependent oligomerisa-
tion of diverse proteins.
Finally, we go on to test and validate the use of this
in vivo BiFC oligomerisation monitoring system in
screens which can be used to not only identify inhibi-
tors of Nt-acetylation but also to identify molecules
that impact the Nt-acetylation-dependent oligomer for-
mation. In a blind trial screen we identified a series of
related Tyrosine kinase inhibitors that promoted the
formation of a-Syn amyloids within the cell. No effect
was seen on the unacetylated form, indicating the
drugs did not impact protein production, cell viability
or interaction between the BiFC fragments. A number
of these drugs have been shown to affect amyloid for-
mation within neuronal cell systems, as well as
improve motor neuron activity in a-synucleinopathy
models, thus providing validation for this E. coli based
drug screen. This provides a simple, cheap and rapid
alternative to current screens (for example [28,29]) and
when used together to validate findings provide a for-
midable tool-kit to identify new and improved thera-
pies against these debilitating diseases.
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Supporting information
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online in the supporting information tab for this
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Fig. S1. (A) Commassie stain (upper panel) and anti-
aSyn western blot (lower panel) analysis of extracts of
BL21(DE3) pET-aSyn-BiFC cells expressing either
NatA (left) or NatB (right). Samples were taken at 0,
1, 3, 5 and 7 h after IPTG addition. (B) Model of
potential conformations of unmodified (upper figure)
and Nt-acetylated (lower figure) aSyn BiFC proteins.
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